Skip to main content

Trials

Displaying 1 - 10 of 450
OR Filter by:
NCT Number Generic Name Title Enrollment* CSR Summary Actions
NCT00473512 Abiraterone acetate A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy 54
NCT00473746 Abiraterone acetate Phase I/II Open Label Dose Escalation Study of the 17α-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer 66
NCT00474383 Abiraterone acetate A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy 47
NCT00485303 Abiraterone acetate A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy 58
NCT00544440 Abiraterone acetate An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone Acetate (CB7630), in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma 57
NCT00638690 Abiraterone acetate A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy 1 195 Download CSR Summary
NCT00887198 Abiraterone acetate A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer 1 088 Download CSR Summary
NCT00924469 Abiraterone acetate A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer 58 Download CSR Summary
NCT01088529 Abiraterone acetate A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone 66
NCT01314118 Abiraterone acetate A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease 131

*These numbers were obtained from Clinical Study Report Summaries, Primary Publications, and ClinicalTrials.gov. Actual numbers may vary.

Don’t see the trial(s) you are looking for?

Submit an Inquiry

Please note: the functionality within this page works best within the following parameters:

  • Internet browser: Mozilla Firefox
  • Pop up blockers disabled
  • Javascript enabled